05/26/22 8:00 AMNasdaq : LNTH Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and FollowRHEA-AInegative
05/16/22 4:30 PMNasdaq : LNTH Lantheus Hosts Inaugural Investor DayLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17,RHEA-AIneutral
05/16/22 8:00 AMNasdaq : LNTH Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual MeetingLantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integratedRHEA-AIneutral
05/13/22 8:00 AMNasdaq : LNTH clinical trialLantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated providerRHEA-AIneutral
05/11/22 8:00 AMNasdaq : LNTH Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate CancerLantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated providerRHEA-AIneutral
05/10/22 8:30 AMNasdaq : LNTH conferencesLantheus to Present at the UBS Global Healthcare ConferenceLantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and FollowRHEA-AIneutral
04/29/22 7:07 AMNasdaq : LNTH earningsLantheus Holdings, Inc. Reports First Quarter 2022 Financial ResultsWorldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to GAAP net income of $9.0 million in the prior year period GAAP fully diluted net income of $0.61 forRHEA-AIneutral
04/15/22 8:30 AMNasdaq : LNTH conferencesearningsLantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern TimeLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Friday, April 29, 2022, to discuss its financial and operating results for the first quarter ofRHEA-AIneutral
04/04/22 8:00 AMNasdaq : LNTH managementLantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical OfficerLantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and FollowRHEA-AIvery positive
03/29/22 8:00 AMNasdaq : LNTH clinical trialLantheus Announces Collaboration to Support Prostate Cancer Clinical DevelopmentLantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH),RHEA-AIvery positive